drugset / Trial / NCT00857649

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857649

Phase 3 Terminated 369 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.

Timeline

Start
2003-12
Primary completion
2010-04
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg Oral

Indications